46 results on '"Helmus, N"'
Search Results
2. Patient and physician reported outcomes of juvenile systemic sclerosis patients significantly improve over 24 months observation period in the juvenile systemic scleroderma inception cohort
3. Diffuse juvenile systemic sclerosis patients show distinct organ involvement, antibody pattern and have significantly more severe disease in the largest jSSc cohort of the world. Results from the juvenile scleroderma inception cohort
4. Is decreased body mass index-2 z score or less correlating with an organ involvement pattern? Results from the juvenile scleroderma inception cohort
5. Diffuse juvenile systemic sclerosis patients show distinct organ involvement, antibody pattern and have significantly more severe disease in the largest jSSc cohort of the world. Results from the juvenile scleroderma inception cohort
6. Is decreased body mass index-2 z score or less correlating with an organ involvement pattern? Results from the juvenile scleroderma inception cohort
7. Patient and physician reported outcomes of juvenile systemic sclerosis patients significantly improve over 24 months observation period in the juvenile systemic scleroderma inception cohort
8. Application of CRISS score, revised CRISS score and RCID score in patients with Juvenile systemic sclerosis
9. Diffuse juvenile systemic sclerosis patients show distinct organ involvement and have more severe disease in the largest jSSc cohort of the world. Results from the the juvenile scleroderma inception cohort
10. Juvenile systemic sclerosis treatment practices in an international cohort and comparison to recent SHARE consensus guidelines
11. Patient and physician reported outcomes of juvenile systemic sclerosis patients significantly improve over 12 months observation period in the juvenile systemic scleroderma inception cohort
12. Diffuse juvenile systemic sclerosis patients show distinct organ involvement and have more severe disease in the largest jSSc cohort of the world. Results from the the juvenile scleroderma inception cohort
13. Juvenile systemic sclerosis treatment practices in an international cohort and comparison to recent SHARE consensus guidelines
14. Patient and physician reported outcomes of juvenile systemic sclerosis patients significantly improve over 12 months observation period in the juvenile systemic scleroderma inception cohort
15. Juvenile systemic sclerosis (jSSc) patients with overlap characteristics do not have mild disease.Results from thejSSc inception cohort
16. Patients with juvenile systemic sclerosis have a distinct pattern of organ involvement. Results from thejuvenile systemic sclerosis inception cohort
17. Juvenile systemic sclerosis (jSSc) patients with overlap characteristics do not have mild disease.Results from thejSSc inception cohort
18. Patients with juvenile systemic sclerosis have a distinct pattern of organ involvement. Results from thejuvenile systemic sclerosis inception cohort
19. Is there a difference in presentation of female and male patients with juvenile systemic scleroderma?
20. Update from the juvenile scleroderma Inception Cohort
21. After 24 months observation period patient reported outcomes improved significantly in the juvenile Scleroderma Inceptions Cohort
22. Is there a difference in presentation of female and male patients with juvenile systemic scleroderma?
23. Patients and physician related outcomes improve significantly over 12 months follow up in patients with juvenile systemic sclerosis. Results from the juvenile scleroderma inception cohort. www.juvenile-scleroderma.com
24. Do Raynaud phenomenon negative juvenile systemic scleroderma patients have a different pattern of organ involvement as Raynaud phenomenon positive patients?
25. Update from the juvenile scleroderma Inception Cohort
26. After 24 months observation period patient reported outcomes improved significantly in the juvenile Scleroderma Inceptions Cohort
27. Patients and physician related outcomes improve significantly over 12 months follow up in patients with juvenile systemic sclerosis. Results from the juvenile scleroderma inception cohort. www.juvenile-scleroderma.com
28. Do Raynaud phenomenon negative juvenile systemic scleroderma patients have a different pattern of organ involvement as Raynaud phenomenon positive patients?
29. Update on the juvenile systemic Sclerosis Inception Cohort Project. Characteristics of the first 97 Patients at first Assessment. www.juvenile-scleroderma.com
30. Is there a Difference in the clinical Presentation of juvenile Systemic Scleroderma Patients according the Age of onset: Results from the juvenile Scleroderma Inception Cohort www.juvenile-scleroderma.com
31. Tocilizumab is a promising treatment option for therapy resistent juvenile localised scleroderma patients
32. Is there a Difference in the Presentation of male and female Patients with diffuse subtype of juvenile systemic Sclerosis? Results from the juvenile Scleroderma Inception Cohort www.juvenile-scleroderma.com
33. Is there a Difference in the clinical Presentation of juvenile Systemic Scleroderma Patients according the Age of onset: Results from the juvenile Scleroderma Inception Cohort www.juvenile-scleroderma.com
34. Tocilizumab is a promising treatment option for therapy resistent juvenile localised scleroderma patients
35. Is there a Difference in the Presentation of male and female Patients with diffuse subtype of juvenile systemic Sclerosis? Results from the juvenile Scleroderma Inception Cohort www.juvenile-scleroderma.com
36. Update on the juvenile systemic Sclerosis Inception Cohort Project. Characteristics of the first 97 Patients at first Assessment. www.juvenile-scleroderma.com
37. Is there a difference in the presentation of male and female patients with juvenile systemic sclerosis? Results from the juvenile scleroderma inception cohort (www.juvenilescleroderma.com)
38. Update on the juvenile systemic sclerosis inception cohort project (www.juvenilescleroderma.com). Characteristics of the first 74 patients at first assessment
39. Is there a difference in the presentation of diffuse and limited subtype in childhood? Results from the juvenile scleroderma inception cohort (www.juvenilescleroderma.com)
40. Is there a difference in the presentation of diffuse and limited subtype in childhood? Results from the juvenile scleroderma inception cohort (www.juvenilescleroderma.com)
41. Is there a difference in the presentation of male and female patients with juvenile systemic sclerosis? Results from the juvenile scleroderma inception cohort (www.juvenilescleroderma.com)
42. Update on the juvenile systemic sclerosis inception cohort project (www.juvenilescleroderma.com). Characteristics of the first 74 patients at first assessment
43. Update on the juvenile systemic sclerosis inception cohort WWW.JUVENILE-SCLERODERMA.COM
44. Is there a difference in the presentaion of diffuse and limited subtype of juvenile systemic sclerosis in childhood? Results from the juvenile scleroderma inception cohort WWW.JUVENILE-SCLERODERMA.COM
45. Update on the juvenile systemic sclerosis inception cohort WWW.JUVENILE-SCLERODERMA.COM
46. Is there a difference in the presentaion of diffuse and limited subtype of juvenile systemic sclerosis in childhood? Results from the juvenile scleroderma inception cohort WWW.JUVENILE-SCLERODERMA.COM
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.